United States: WilmerHale Reps Editas Medicine In Licensing Of New Technologies
Last Updated: January 5 2017

Editas Medicine, Inc., a leading genome editing company, announced it has exclusively licensed intellectual property related to new CRISPR technologies for human therapeutics that will enhance and broaden the range of medicines the company can develop. These global licensing agreements include intellectual property owned by the Broad Institute of MIT and Harvard (Broad Institute), Harvard University, Massachusetts Institute of Technology (MIT), Wageningen University, the University of Iowa, and the University of Tokyo for the new CRISPR genome editing system.

The WilmerHale deal team included Partners Steven Barrett and Rosemary Reilly; Counsel Jeffries Oliver-Li, Associates Hilary Baker-Jennings and Brett Bromann; and Attorney Heidi Treiber.

Read the press release published by Editas Medicine for more information.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Leila Gaafar
By Timothy Silva, Seth Davis
By Christopher Babbitt, Jonathan Bressler, Claire Chung
By WilmerHale
By Jonathan Yarowsky, Perry A. Lange, Hartmut Schneider, Leon Greenfield, D. Reed Freeman, Jr., Heather Zachary
By Jay Holtmeier, Erin Sloane
By Geoffroy Barthet, Nicole Callan, Cormac O'Daly, Hartmut Schneider
By WilmerHale
By WilmerHale
By Alan Wilson, Jonathan Wolfman
Tools
Print
Font Size:
Translation
Channels